Janssen Announces European Commission Approval of Darzalex®▼ (daratumumab) as Frontline Treatment for Newly Diagnosed Patients with Multiple Myeloma Who are Transplant Ineligible
- EMEA Innovative Medicine
- Janssen Announces European Commission Approval of Darzalex®▼ (daratumumab) as Frontline Treatment for Newly Diagnosed Patients with Multiple Myeloma Who are Transplant Ineligible
Janssen Announces European Commission Approval of Darzalex®▼ (daratumumab) as Frontline Treatment for Newly Diagnosed Patients with Multiple Myeloma Who are Transplant Ineligible
- X (Twitter)
Copy link